Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

Advancing Care in Lupus Nephritis: Expert Perspectives on Current Practices and Future Directions in Italy.

Journal of clinical medicine·2026
Same author

Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study.

Rheumatology (Oxford, England)·2026
Same author

A field-deployable immunofluorescence chip for adenovirus monitoring in groundwater systems.

Biosensors & bioelectronics·2026
Same author

Chronic kidney disease trajectories in lupus nephritis: Is progression unavoidable?

Journal of autoimmunity·2026
Same author

Diagnostic challenge of high vitamin B12 levels: a case report and review of the literature.

Journal of medical case reports·2026

Related Experiment Video

Updated: Mar 11, 2026

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

3.2K

Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis.

Mandy Sowa1, Barbara Trezzi, Rico Hiemann

  • 1Research and Development Department, GA Generic Assays GmbH, Dahlewitz/Berlin, Germany Clinical Immunology, San Carlo Borromeo Hospital, Milan, Italy Institute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg Research and Development Department, Medipan GmbH, Dahlewitz/Berlin, Germany Department of Medicine and Surgery, Università degli Studi di Milano - Bicocca (School of Medicine and Surgery), via Cadore, 48 - 20900 Monza (MB) Microbiology Institute, San Carlo Borromeo Hospital, Milan, Italy.

Medicine
|November 19, 2016
PubMed
Summary

A novel multiplex assay using CytoBead technology allows simultaneous detection of autoantibodies associated with rapidly progressive glomerulonephritis (RPGN). This method offers a promising, efficient alternative for early diagnosis and timely treatment of RPGN, potentially preventing kidney failure.

More Related Videos

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
05:25

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

Published on: July 14, 2023

2.0K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

3.2K
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
05:25

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

Published on: July 14, 2023

2.0K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.4K

Area of Science:

  • Nephrology
  • Immunology
  • Diagnostic Technology

Background:

  • Rapidly progressive glomerulonephritis (RPGN) is a severe kidney disease often caused by anti-glomerular basement membrane (GBM) antibody disease, immune-complex glomerulonephritis, or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides.
  • Early diagnosis and treatment are crucial to prevent end-stage renal disease.
  • Detection of specific autoantibodies, including ANCA, anti-GBM, and anti-dsDNA, is key for RPGN diagnosis.

Purpose of the Study:

  • To evaluate the diagnostic performance of a novel multiplex CytoBead technology for simultaneous detection of autoantibodies relevant to RPGN.
  • To compare the CytoBead assay with classical single testing methods for ANCA, myeloperoxidase (MPO-ANCA), proteinase 3 (PR3-ANCA), anti-GBM autoantibodies, and anti-dsDNA autoantibodies.

Main Methods:

  • The study utilized a multiplex CytoBead assay based on automated indirect immunofluorescence (IIF) to analyze autoantibodies in patients with various kidney diseases (GPA, MPA, SLE, GPS) and healthy subjects.
  • Patient cohorts included 40 with granulomatosis with polyangiitis (GPA), 48 with microscopic polyangiitis (MPA), 42 with systemic lupus erythematosus (SLE), 43 with Goodpasture syndrome (GPS), 57 with infectious diseases (INF), and 55 healthy subjects (HS).
  • Assay performance was assessed by calculating diagnostic sensitivities and specificities, and agreement with conventional methods (ELISA, IIF) was evaluated.

Main Results:

  • The CytoBead assay demonstrated high diagnostic sensitivities for RPGN-associated autoantibodies: PR3-ANCA (85.0%), MPO-ANCA (77.1%), anti-GBM autoAb (88.4%), anti-dsDNA autoAb (83.3%), and ANCA (91.1%).
  • Specificities for healthy and infectious disease groups were also high, ranging from 96.4% to 100.0%.
  • Excellent agreement was observed between the CytoBead assay and classical methods for anti-GBM autoAb, MPO-ANCA, PR3-ANCA, and ANCA, though fair agreement was noted for anti-dsDNA autoAb.

Conclusions:

  • The CytoBead technology offers a robust multiplex platform for simultaneous detection of RPGN-specific autoantibodies.
  • This assay is a promising alternative to conventional, time-consuming single-parameter tests, particularly suitable for emergency diagnostics.
  • The multiplex approach aids in the early and accurate diagnosis of RPGN, facilitating prompt treatment and potentially preserving renal function.